The protein kinase inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) was found to inhibit the growth of two different mycobacterial strains, the slow-growing Mycobacterium bovis Bacille Calmette Guerin (BCG) and the fast-growing saprophyte Mycobacterium smegmatis mc 2 155, in a dose-dependent manner. While screening for the effect of kinase inhibitors on mycobacterial growth, millimolar concentrations of H7 induced a 40% decrease in the growth of M. bovis BCG when measured as a function of oxidative phosphorylation. This H7-induced decrease in growth was shown to involve a 2-log fold decrease in the viable counts of M. smegmatis within a 48-h period and a 50% reduction in the number of BCG viable counts within a 10-day period. Micromolar concentrations of H7 compound induced a significant decrease in the activity of the Mycobacterium tuberculosis protein serine/threonine kinase (PSTK) PknB. The inhibition of mycobacterial growth as well as the inhibition of a representative M. tuberculosis protein serine/threonine kinase PknB suggests that conventional PSTK inhibitors can be used to study the role that the mycobacterial PSTK family plays in controlling bacterial growth. ß
Introduction
Tuberculosis (TB) is the leading cause of death in the world from a single bacterial agent [1] . From the late 1980s onward, there has been a re-emergence of TB within the industrialized world [1] . Unfortunately, the lack of novel therapeutics against this pathogen is coupled with a growing resistance to current antimycobacterial therapies [2] , stressing the need for the discovery of novel antimycobacterial agents to aid in the battle against TB.
Protein kinases are key bacterial intracellular elements of signal transduction pathways that control gene expression, modulate metabolic processes and allow the cells to respond to the constantly changing extracellular conditions [3] . Within this paradigm, small molecules that inhibit protein kinases are currently being considered as novel therapeutic candidates against cancer [4] , endocrine disorders [5] , in£ammation and shock [6] .
In the past, it was thought that intracellular signalling in bacteria primarily involved two-component phosphorelay systems [7] . This view of bacterial kinases changed with the discovery of eukaryotic-like (PSTKs) in bacteria [81 2] . Eleven putative protein serine/threonine kinases (PSTK's) were identi¢ed in the Mycobacterium tuberculosis H37Rv genome and several have been con¢rmed to be active PSTKs [13, 9] . PSTKs expressed by bacteria presumed to act by interfering with host cellular signalling mechanisms during development or pathogenesis [9, 14] . Although M. tuberculosis PSTKs are phylogenetically distinct [9, 11, 12] , they contain all 12 distinct Hank's kinase subdomains [8, 15] . Further genome analysis work showed that PSTK homologs are present in other mycobacteria such as Mycobacterium bovis Bacille Calmette Guerin (BCG) and Mycobacterium smegmatis [16, 17] . This contrasts to the Gram-negative facultative aerobes such as Escherichia coli which lack any homology to PSTKs [9] . The fast-growing nature of M. smegmatis plus the fact that both this bacillus and BCG are non-pathogenic in normal healthy humans makes them excellent candidates for studies of bacterial growth inhibition. Among the small molecule kinase inhibitor candidates, the H-series sulfonyl compound 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) inhibits protein kinase activity by competitively inhibiting ATP interactions with the Hank's domains I to IV [15] in eukaryotic-like kinases [18] .
In this paper, we report that H7 limits the growth of two mycobacterial species. Furthermore, we also show that this isoquinoline directly inhibits the protein serine/ threonine kinase PknB in vitro. 
Materials and methods

2
Growth of mycobacterial strains
BCG Pasteur was grown in 7H9 media with oleic acid, albumin, dextrose and catalase (OADC) and 0.5% Tween-80 at 37³C with shaking at 50 rpm in 50-ml screw top tubes. M. smegmatis was grown in LB media and plated onto LB agar.
Measurement of bacterial growth using alamarBlue1
A variety of compounds including 0 mM to 30 mM H7, 0 WM to 0.5 WM of the phosphatidyl inositol (PI) 3-kinase inhibitor wortmannin, 0 mM to 4 mM of alkyloid-like kinase inhibitor K252a from Nocardiopsis [19] , and 0 WM to 6 WM of the phosphatase inhibitor okadaic acid were tested against BCG cultures using a microplate alamarBlue1 assay (Accumed International, Westlake, OH, USA) [20] . BCG was grown in 7H9 media at 37³C as described above. Bacteria were diluted to 1U10 6 CFUs in 7H9 media as previously described [20] and were treated with varying doses of kinase inhibitors. Measurement of optical densities were done as previously described [21] Media-only controls, alamarBlue1 in media controls, BCG growth controls, and drug treatments were utilized to calculate the percent reduction of the culture [21] , which is directly related to mycobacterial cell growth [20] .
Viable count assays for BCG and M. smegmatis
Mycobacteria were grown as described above. At an OD 600 nm of 0.4^0.7, total CFUs were determined for later data transformation (see Eq. 1). The cultures were diluted by a factor of 2.5 in culture media and treated with limiting doses of 3 mM H7, 0.03 mM hygromycin or dH 2 0 (control), and were grown in snaptop 1.5 ml tubes at 37³C, 50 rpm. Hygromycin was used in all viable count assays to control for bacterial growth inhibition because it is not a ¢rst-line antibiotic and can be used routinely without causing ¢rst-line drug resistance. At selected drug treatment times, bacteria were harvested and washed two times in culture media at 15 000Ug, 3 min at room temperature. Bacteria were diluted in 7H9 media to 10 34 , 10 35 and 10
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and 100 Wl were plated onto 7H10 plates containing OADC for BCG. Colony forming units (CFUs) were enumerated after an incubation period of 3 weeks at 37³C. M. smegmatis mc 2 155 were grown in LB media and plated onto LB agar.
Data analysis of mycobacterial viability counts
We decided to standardize the measures of viability and expressed them as % viability or log (% of viability) compared to the initial bacilli input. Since BCG was not in exponential phase growth, this growth was expressed as a percentage of viability. In contrast, M. smegmatis entered exponential phase growth and could be expressed as such. This transformation allowed for us to standardize the effect of drugs, solvents and handling on mycobacterial survival over independent experiments.
The following transformations of raw data were done for both BCG and M. smegmatis.
Eq. 1: Calculation of relative growth (%) of mycobacteria.
Relative growth % treated CFUU100%U initial dilution factorUCFU stock culture 31 1 For M. smegmatis experiments, an additional transformation of data was done due to greater variability between initial stock CFUs used and the entry of this bacteria into exponential phase growth.
Eq. 2: Log transformation of relative growth (%) of mycobacteria.
Log relative growth % log treated CFUU100%U initial dilution factorUCFU stock culture 31 2
PknB kinase assays
Kinase assays were done at room temperature with the addition of dH 2 O or increasing concentrations of H7, diluted in dH 2 O, at both 0-and 15-min time points. Reaction conditions were identical to those described in a previous study [22] . Reactions were stopped by addition of Laemmli's SDS^PAGE sample loading bu¡er. Proteins were separated by 12% SDS^PAGE and PknB-mediated MBP phosphorylation was detected by autoradiography [22] . The inhibitory e¡ect of increasing doses of H7 on PknB-mediated MBP phosphorylation was evaluated by densitometry of the autoradiography. Relative densities of MBP phosphorylation bands were measured by densitometry (Bio-Rad Quantity One 0 ).
Results
Screening of multiple kinase inhibitors against BCG
Conventional PSTK inhibitors such as the PI3-kinase inhibitor wortmannin, H7, K-252a and the protein serine^threonine phosphatase inhibitor okadaic acid were chosen as candidate drugs against BCG. Due to the presence of the hydrophobic layers of mycolic acid layer and cell membrane, the doses chosen were in excess of those used in eukaryotic models. These experiments showed that at the highest concentration tested, the PI3-kinase inhibitor wortmannin (0.5 WM), the alkyloid-like kinase inhibitor K252a from Nocardiopsis (4 mM), and the phosphatase inhibitor okadaic acid (6 WM) failed to inhibit the growth of BCG (data not shown).
On the other hand, H7 was able to limit the growth of BCG in liquid culture. As shown in Fig. 1 , a dose of 20 Wg ml 31 (3 mM) of H7 decreased the growth of BCG cultures, as measured by oxidative phosphorylation, to a level that was 60% of untreated culture. This decrease in bacterial growth is roughly equivalent to that obtained by 20 Wg ml 31 (0.035 mM) of the bactericidal antibiotic hygromycin.
To exclude the possibility that the e¡ect of H7 was due to a non-speci¢c toxic e¡ect, the e¡ect of H7 on E. coli HB101 was examined. E. coli lacks any PSTKs and indeed its growth was not inhibited by concentrations of up to 3 mM H7, 24 h growth (data not shown).
H7 limits M. smegmatis growth over a 48-h period as measured by viable count
To answer whether H7 directly inhibits bacterial growth, M. smegmatis mc 2 155 was chosen because of its rapid growth rate. The M. smegmatis genome contains PSTK homologs that might act as targets for the inhibitor H7. Since alamarBlue1 is a redox indicator and the assays took place within a relatively short period of time, we could not distinguish if the observed changes were due to an actual decrease in mycobacterial growth or the limiting of some redox-a¡ecting metabolic process such as oxidative phosphorylation.
A dose response to H7 was evaluated after 24 h of growth or approximately 4^7 generations since the halflife of H7 in these culture conditions was not known. As shown in Fig. 2, H7 has a dose-dependent inhibitory e¡ect on M. smegmatis growth. A maximal dose of 3 mM H7 induced a one-log decrease in M. smegmatis CFUs when compared to solvent only groups. In the positive control group for killing, 0.03 mM hygromycin induced a decrease in M. smegmatis viable count.
To identify the optimal time for H7 inhibition of M. smegmatis growth, bacteria were treated over 0^48 h. In three separate experiments (Fig. 3) , a limiting dose of 3 mM H7 induced a two-log decrease in M. smegmatis growth when compared to solvent treatment controls within 24 h. As a control for mycobacterial killing, a dose of 0.03 mM hygromycin cleared plates within a within a 24-h period. This series of time course experiments con¢rm the initial dose^response experiments and provided evidence that the inhibitory e¡ect of H7 is evident over a period of several mycobacterial generations. 
H7-limited BCG growth correlates to a decrease in viable counts over a 10-day period
To determine if the initial decrease in BCG culture oxidative phosphorylation, from the alamarBlue1 experiments, correlated to a decrease in its viability in liquid media. A time course assay over a 10-day period using the limiting doses of drugs optimized in the initial screening experiments was carried out [23] . Over three separate experiments, the inhibitor H7 (3 mM) induced a 50% decrease in the relative percentage growth (mean þ S.E.M.) of BCG when compared to non-treatment groups at the 10-day period (Fig. 4) . The data in Fig. 4 also show that the positive control, 0.03 mM hygromycin, e¡ectively kills BCG throughout the same time period. These experiments con¢rmed that the H7-induced growth inhibition seen in the initial alamarBlue1 screening experiments was due to the limitation of BCG viability and not due to interference with some other metabolic process.
H7 inhibits PknB activity in vitro
It is necessary to correlate the inhibition of mycobacterial growth by H7 to the inhibition of a mycobacterial kinase for two reasons. First, in addition to being a kinase inhibitor, H7 has also been shown to inhibit other molecular targets, such as RNA polymerase II, which are involved in growth and development [24] . Secondly, since H7 has a variable e¡ect on eukaryotic kinases, there was some question as to whether mycobacterial PSTKs could actually be inhibited by this small molecule. To determine if H7 could indeed target mycobacterial PSTKs, we performed in vitro kinase assays using the M. tuberculosis kinase PknB previously studied with MBP as an arti¢cial substrate. A dose of 6 WM H7 was su¤cient to inhibit PknB-mediated phosphorylation of MBP by 81% when compared to solvent alone (Fig. 5 ). This di¡erence between 0 WM and 6 WM H7 is signi¢cant as judged by Friedman's non-parametric analysis of variation (n = 5, Friedman's Statistic 9.960, four groups, P = 0.0087 and Dunn's multiple comparison test n = 5, P 6 0.05). These data imply that a member of the family of mycobacterial PSTKs is one of the targets for H7 in mycobacteria.
Discussion
Although the kinase inhibitors genistein, staurosporine and K252a inhibit the development of the bacteria Myxococcus xanthus [25] and Streptomyces species [19] , this experiment is the ¢rst description of an isoquinoline having an e¡ect against members of the Mycobacterium genus. H7 was most e¡ective in reducing the growth of M. smegmatis in LB but also showed an inhibitory e¡ect against M. bovis BCG in 7H9 media containing OADC. H7 did not cause inhibition of mycobacterial growth on solid growth media (data not shown). This may be due to several important di¡erences between solid and liquid media. For example, concentrations of several ions such as those provided by sodium citrate, disodium phosphate and Magnesium sulfate di¡er between the two media types. Mycobacterial PSTK activity was shown in the past to be effected by divalent metallic cations [22] . Furthermore, solid 7H10 media also contain several components, such as malachite green and agar, that are not presently seen in liquid media and may e¡ect H7 activity. Previous work in enterococci suggests that proteins and carbohydrates, which may be present in agar, can change the e¡ect of some growth-modifying chemicals [26] . In addition, it is well established that di¡erent growth kinetics are typical of mycobacteria growing on solid media vs. mycobacteria grown on equivalent liquid media [27, 28] . As a result, H7 may have a greater accessibility to bacteria in liquid media than in solid media.
The impressive H7-induced inhibition of M. smegmatis growth may have also been due to the relatively quick generation time of the bacteria as well as the stressful conditions faced in LB media [23] . Since the half-life of H7 is not known, it is possible that H7 stability may be the reason for higher sensitivity of the fast-growing M. smegmatis when compared to the slow-growing BCG.
The relatively high dose of H7 required to inhibit mycobacterial growth could be due to two factors. First, the presence of a thick lipid-rich outer envelope may act as a barrier to water-soluble drugs such as H7 [29] . Second, although PSTKs are present in both species of mycobacteria tested, little was know about the e¡ect that conventional PSTK inhibitors have on mycobacterial PSTKs prior to this study. Since PSTK inhibitors have variable activity against a wide variety of targets [25, 18] , it is possible that only a few mycobacterial kinases out of a nearly a dozen potential targets are inhibited following treatment with H7.
These inhibition studies are important because they strengthen the correlation between mycobacterial PSTKs and the control of bacterial growth as hypothesized earlier [9] . Studying the co-e¡ect of PSTK inhibitors with conventional antibiotics and environmental stressors will lead to a better understanding of the signalling mechanisms involved in mycobacterial growth responses to stresses. Another future development may also be the development of new anti-microbial drug combinations involving PSTK inhibitors and conventional antibiotics. This is the ¢rst demonstration that micromolar concentrations of a conventional isoquinoline have an inhibitory e¡ect on a mycobacterial kinase. Although we have shown that H7 is active against PknB, we do not rule out the possibility that it is active against other members of the PSTKs in mycobacteria. The correlation between the inhibition of both kinase activity and mycobacterial growth strengthen our argument that mycobacterial PSTKs are required mycobacterial growth factors [9, 22] .
